Phase I study of domatinostat (4<scp>SC</scp>‐202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies - Concepedia

Concepedia

Publication | Closed Access

Phase I study of domatinostat (4<scp>SC</scp>‐202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies

46

Citations

8

References

2018

Year

Bastian von Tresckow, Cyrus Sayehli, Walter E. Aulitzky, Maria‐Elisabeth Goebeler, Matthias Schwab, Eunice Braz, Babett Krauss, Rolf Krauss, Frank Hermann, René Bartz,

European Journal Of Haematology

Abstract

Administration of domatinostat was safe, well tolerated with signs of antitumor activity. Four hundred milligram TDD in a 200 mg BID schedule (14 + 7) is the recommended phase II dose for monotherapy.

References

	Year	Citations

Page 1